Elite Pharmaceuticals ELTP
OTC ELTP
$0.35 +0.03 (+10.69%)
As of: Nov 16, 2026 · 12:13 PM EST

Elite Pharmaceuticals (ELTP) Research & Development (2009 - 2026)

Updated

Elite Pharmaceuticals (ELTP) recorded Research & Development of $1.88 million in fiscal Q2 2027 (quarter ended Sep 30, 2026), up 35.5% from $1.39 million a year earlier but down 7.7% from the prior quarter.

Analysis

Elite Pharmaceuticals (ELTP) Research & Development (2009 - 2026) Analysis & Trends

On a TTM basis, Elite Pharmaceuticals' Research & Development came in at $6.59 million as of Sep 30, 2026, down 4.4% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $5.74 million, down 27.9% from FY2025.

  • Annual Research & Development has a five-year compound annual growth rate of 2.4% (FY2021 to FY2026).
  • Across earlier fiscal years, Research & Development came in at $7.96 million in FY2025 (+15.7%), $6.88 million in FY2024 (+11.0%), $6.2 million in FY2023 (+53.0%) and $4.05 million in FY2022 (-20.8%).
  • Quarterly Research & Development has ranged from $738,809 in fiscal Q4 2022 to $2.62 million in fiscal Q2 2024 over the past five years.
  • On a year-over-year basis, Research & Development rose in four of the last eight quarters, with an average decline of 1.3%.
  • Peak year-over-year performance for Research & Development in the last five years was growth of 228.2% in fiscal Q4 2023, against a decline of 58.4% in fiscal Q4 2022 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at $2.03 million (Q1 2027), $1.64 million (Q4 2026) and $1.04 million (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,293.04 Bn 1,266.66 Bn 20.46 Bn 4.25 Bn
2 Johnson & Johnson 686.83 Bn 606.69 Bn 17.30 Bn 4.65 Bn
3 AbbVie 525.76 Bn 493.76 Bn 13.12 Bn 2.57 Bn
4 Merck 362.73 Bn 325.68 Bn 13.19 Bn 4.54 Bn
5 Novartis Ag 313.98 Bn 287.22 Bn - -
6 Astrazeneca 287.17 Bn 260.69 Bn 13.26 Bn 3.89 Bn
7 Amgen 253.65 Bn 205.30 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 210.81 Bn 185.92 Bn 6.73 Bn 1.61 Bn
9 Pfizer 165.44 Bn 112.80 Bn 12.56 Bn 3.02 Bn
10 Elite Pharmaceuticals 373.77 Mn 247.18 Mn 15.99 Mn 1.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1.88 Mn
Jun 30, 2026 2.03 Mn
Mar 31, 2026 1.64 Mn
Dec 31, 2025 1.04 Mn
Sep 30, 2025 1.39 Mn
Jun 30, 2025 1.67 Mn
Mar 31, 2025 2.04 Mn
Dec 31, 2024 1.79 Mn
Sep 30, 2024 1.97 Mn
Jun 30, 2024 2.16 Mn
Mar 31, 2024 1.72 Mn
Dec 31, 2023 1.40 Mn
Sep 30, 2023 2.62 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2023 2.43 Mn
Dec 31, 2022 1.44 Mn
Sep 30, 2022 1.23 Mn
Jun 30, 2022 955,443.00
Mar 31, 2022 738,809.00
Dec 31, 2021 956,628.00
API Access

Elite Pharmaceuticals Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=ELTP&period=max&api_key=YOUR_API_KEY